title: Radionuclide Therapy of Unresectable Tumors with AvidinOX and (90)Y-biotinDOTA: Tongue Cancer Paradigm.
abstract: Local treatment of unresectable tumors is challenging, particularly with radioactivity. Current practice relies on external beam irradiation or on a variety of medical devices for brachytherapy. Both approaches proved useful in controlling tumor growth, but are characterized by poor compliance of the patient, significant side-effects, high costs, and technological complexity, which hamper widespread use. The authors recently described a novel form of radionuclide therapy based on the oxidized form of avidin that, chemically reacting with tissue proteins, can secure radioactive biotin within the injected tissue, either when precomplexed or when taken from the blood stream after intravenous administration. AvidinOX-pretargeted (177)Lu-biotinDOTA ((177)Lu-ST2210) is currently under clinical investigation for the treatment of liver oligometastases from colorectal cancer (clinicaltrials.gov/NCT02053324). In the present work, the authors show that injected AvidinOX can link tissues of various natures such as prostate, kidney, breast, or brain and can react by contact with scraped tissues such as skin or urinary bladder. AvidinOX injected into human OSC19 tongue cancer masses orthotopically transplanted in nude mice takes up intravenously administered (90)Y-ST2210, which exerts significant antitumor activity, while preserving the integrity and functionality of the tongue. Present data confirm that AvidinOX-based radionuclide therapy is an innovative and promising approach for the local treatment of inoperable tumors.
authors.affiliation: 1 Department of Biotechnology, Sigma-Tau SpA , Pomezia, Rome, Italy .
authors.forename: Claudio
authors.initials: C
authors.lastname: Albertoni
authors.affiliation: 1 Department of Biotechnology, Sigma-Tau SpA , Pomezia, Rome, Italy .
authors.forename: Barbara
authors.initials: B
authors.lastname: Leoni
authors.affiliation: 1 Department of Biotechnology, Sigma-Tau SpA , Pomezia, Rome, Italy .
authors.forename: Antonio
authors.initials: A
authors.lastname: Rosi
authors.affiliation: 1 Department of Biotechnology, Sigma-Tau SpA , Pomezia, Rome, Italy .
authors.forename: Valeria
authors.initials: V
authors.lastname: D'Alessio
authors.affiliation: 2 Department of Histopathology, Histo-Cyto Service , Rome, Italy .
authors.forename: Valeria
authors.initials: V
authors.lastname: Carollo
authors.affiliation: 2 Department of Histopathology, Histo-Cyto Service , Rome, Italy .
authors.forename: Luigi Giusto
authors.initials: LG
authors.lastname: Spagnoli
authors.affiliation: 3 ABX-CRO , Dresden, Germany .
authors.forename: Cees
authors.initials: C
authors.lastname: van Echteld
authors.affiliation: 1 Department of Biotechnology, Sigma-Tau SpA , Pomezia, Rome, Italy .
authors.forename: Rita
authors.initials: R
authors.lastname: De Santis
mesh_terms: D000818:Animals; D001360:Avidin / Q000008:administration & dosage*; D001710:Biotin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004285:Dogs; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009942:Organometallic Compounds / Q000008:administration & dosage*; D011817:Rabbits; D016499:Radioimmunotherapy; D013552:Swine; D014062:Tongue Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D015021:Yttrium Radioisotopes / Q000008:administration & dosage*
chemical_list: C405616:DOTA-biotin; D009942:Organometallic Compounds; D015021:Yttrium Radioisotopes; D001360:Avidin; D001710:Biotin
keywords: AvidinOX; biotin; radionuclide therapy; tongue cancer